Sheep anti Human Glypican-3 (GPC3)
| Code | Size | Price |
|---|
| EXA-X2395P | 500 ug | £316.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Sheep
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Shipping:
Ship at ambient temperature freeze upon arrival
Storage:
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Further Information
Applications Description:
Antibody can be used for immunohistochemistry on paraffin-embedded tissues (10 ?g/ml) and Western blotting (5-10 ?g/ml). Optimal concentration should be evaluated by serial dilutions.
Background:
Glypican-3 encodes a putative extracellular proteoglycan that is inferred to play an important role in growth control in embryonic mesodermal tissues in which it is selectively expressed. It appears to form a complex with insulin-like growth factor and hence modulate IGF2 action. Glypican-3 is the human homolog of OCI-5, a GPI-linked proteoglycan first isolated from rat intestine. Originally identified as the molecular basis for Simpson-Golabi-Behmel syndrome (SGBS) also called Simpson dysmorphia syndrome (SDYS).
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
See vial for concentration
Field of Interest:
Oncology
Formulation:
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Functional Analysis:
Immunohistochemistry
Immunogen:
C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)
Product Form:
Unconjugated
Product Stability:
Products are stable for one year from purchase when stored properly
Purification Method:
Total IgG
Synonyms:
GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7
UniProt:
P51654
References
1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222.
2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230.
3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223.
4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394.
5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224.
6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906.
7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711.
8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990.
9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.
2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230.
3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223.
4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394.
5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224.
6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906.
7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711.
8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990.
9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.